Mainz Biomed (NASDAQ: MYNZ) files Form 6-K with H1 2025 MD&A and unaudited financials

Rhea-AI Filing Summary

Mainz Biomed N.V. filed a Form 6-K as a foreign private issuer for the six months ended June 30, 2025. The company made available its Management’s Discussion and Analysis of Financial Condition and Results of Operations for this six-month period as Exhibit 99.1.

It also provided its unaudited financial statements as of, and for, the six months ended June 30, 2025 as Exhibit 99.2. These documents are incorporated by reference into Mainz Biomed’s existing shelf registration statement on Form F-3 and its equity compensation registration statement on Form S-8, allowing those offerings to rely on the updated interim financial and narrative information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 09/26/2025 - 05:00 PM Learn about SEC filing dates

FAQ

What did Mainz Biomed (MYNZ) file in this Form 6-K?

Mainz Biomed N.V. filed a Form 6-K providing its Management’s Discussion and Analysis of Financial Condition and Results of Operations for the six months ended June 30, 2025 as Exhibit 99.1 and its unaudited interim financial statements for the same period as Exhibit 99.2.

Which period do the new Mainz Biomed (MYNZ) financials on Form 6-K cover?

The materials attached to the Form 6-K cover the six months ended June 30, 2025, including both the MD&A discussion and the unaudited financial statements.

How does this Form 6-K affect Mainz Biomed’s (MYNZ) existing registration statements?

The Form 6-K and Exhibits 99.1 and 99.2 are incorporated by reference into Mainz Biomed’s existing registration statement on Form F-3 (File No. 333-269091) and its Form S-8 (File No. 333-273203), so those registrations now include the latest interim information.

Are the financial statements in this Mainz Biomed (MYNZ) Form 6-K audited?

The Form 6-K specifies that the attached financial statements for the six months ended June 30, 2025 are unaudited.

What additional technical exhibits are included with Mainz Biomed’s (MYNZ) Form 6-K?

The filing includes various Inline XBRL data files (instance, schema, calculation, definition, label, and presentation linkbase documents) and a cover page interactive data file, supporting structured data reporting.

Who signed the Mainz Biomed (MYNZ) Form 6-K?

The Form 6-K was signed on behalf of Mainz Biomed N.V. by William J. Caragol, the company’s Chief Financial Officer, dated September 26, 2025.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the six months ended June 30, 2025

Commission File No. 001-41010

MAINZ BIOMED N.V.

(Translation of registrant’s name into English)

Robert Koch Strasse 50
55129 Mainz
Germany

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒     Form 40-F ☐

Other Events

On September 26, 2025, Mainz Biomed N.V. made available its Management’s Discussion and Analysis of Financial Condition and Results of Operations for the six months ended June 30, 2025. A copy of the report is attached hereto as Exhibit 99.1.

On September 26, 2025, Mainz Biomed N.V. made available its unaudited Financial Statements for the six months ended June 30, 2025. A copy of the report is attached hereto as Exhibit 99.2.

This current report on Form 6-K and exhibits 99.1 and 99.2 hereto are hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-269091) and its registration statement on Form S-8 (File No. 333-273203).

Exhibit No.		Exhibit
99.1		Management’s Discussion and Analysis of Financial Condition and Results of Operations of Mainz Biomed N.V. for the six months ended June 30, 2025
99.2		Unaudited Financial Statements of Mainz Biomed N.V. as of, and for the six months ended, June 30, 2025
101.INS		Inline XBRL Instance Document.
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 26, 2025	By:	/s/ William J. Caragol
	Name:	William J. Caragol
	Title	Chief Financial Officer

2